oral drug, covalent inhibitor of KRASG12C
effective in KRASG12C-mutated cancer models
SBDD utilizing KRAS proto-oncogene, GTPase
British Journal of Cancer
Astellas Pharma Inc.
ASP2453
3. The Astellas KRASG12C covalent inhibitor, ASP2453, is an oral molecule with activity in preclinical mouse models of KRASG12C-mutated cancer at lower doses than sotorasib (AMG 510). Several KRAS inhibitors have…